Mitochondrial fusion: A mechanism of cisplatin-induced resistance in neuroblastoma cells?

NeuroToxicology

Volumn 34, Issue 1, 2013, Pages 51-60

  Santin, Giada ^a   Piccolini, Valeria M ^a   Barni, Sergio ^a   Veneroni, Paola ^a   Giansanti, Vincenzo ^a   Dal Bo, Veronica ^a   Bernocchi, Graziella ^a   Bottone, Maria Grazia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Apoptosis; B50 neuroblastoma rat cells; Cisplatin; Drug resistance; Mitochondria

Indexed keywords

ACTIN; APOPTOSIS INDUCING FACTOR; BETA TUBULIN; BETA TUBULIN 3; CISPLATIN; CYTOCHROME C; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN OPA1; SIRTUIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRUCTURE; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG RESISTANCE; FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; MITOCHONDRIAL FUSION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; CYTOCHROMES C; DNA, MITOCHONDRIAL; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GTP PHOSPHOHYDROLASES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; NEUROBLASTOMA; NEURONS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SIRTUIN 1; TIME FACTORS;

RATTUS;

EID: 84870384667     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.10.011     Document Type: Article

References (70)

1. Aida T., Takebayashi Y., Shimizu T., Okamura C., Higasimoto M., Kanzaki A., et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol 2005, 97:41-45.
2. Anand R., Langer T., Baker M.J. Proteolytic control of mitochondrial function and morphogenesis. Biochim Biophys Acta 2012, 10.1016/j.bbamcr.2012.06.025.
3. Bernocchi G., Bottone M.G., Piccolini V., Dal Bo V., Santin G., De Pascali S.A., et al. Developing central nervous system and vulnerability to platinum compounds. Chemother Res Pract 2011, 2011:315418.
4. Bodenner D.L., Dedon P.C., Keng P.C., Katz J.C., Borch R.F. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res 1986, 46:2751-2755.
5. Bottone M.G., Soldani C., Veneroni P., Avella D., Pisu M.B., Bernocchi G. Cell proliferation, apoptosis and mitochondrial damage in rat B50 neuronal cells after cisplatin treatment. Cell Prolif 2008, 41:506-520.
6. Braschi E., McBride H.M. Mitochondria and the culture of the Borg: understanding the integration of mitochondrial function within the reticulum, the cell, and the organism. Bioessays 2010, 32:958-966.
7. Brozovic A., Fritz G., Christmann M., Zisowsky J., Jaehde U., Osmak M., et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004, 112:974-985.
8. Cavaletti G., Marzorati L., Bogliun G., Colombo N., Marzola M., Pittelli M.R., et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203-207.
9. Cepeda V., Fuertes M.A., Castilla J., Alonso C., Quevedo C., Perez J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007, 7:3-18.
10. Cerri S., Piccolini V.M., Santin G., Bottone M.G., De Pascali S.A., Migoni D., et al. Developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum. Neurotoxicol Teratol 2011, 33:273-281.
11. Chen H., McCaffery J.M., Chan D.C. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2006, 130:548-562.
12. Chen H.H., Kuo M.T. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010, pii: 430939.
13. Cipolat S., de Brito O.M., Dal Zillo B., Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA 2004, 101:15927-15932.
14. D'Alessio M., De Nicola M., Coppola S., Gualandi G., Pugliese S., Cerella C., et al. Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J 2005, 19:1504-1506.
15. Daugas E., Susin S.A., Zamzami N., Ferri K.F., Irinopoulou T., Larochette N., et al. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 2000, 14:729-739.
16. Dietrich J., Han R., Yang Y., Mayer-Pröschel M., Noble M. CNS progenitor cells and oligodendrocytes are target of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5:22.
17. Estaquier J., Vallette F., Vayssiere J.L., Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol 2012, 942:157-183.
18. Feldman D.R., Bosl G.J., Sheinfeld J., Motzer R.J. Medical treatment of advanced testicular cancer. JAMA 2008, 299:672-684.
19. Ferree A., Shirihai O. Mitochondrial dynamics: the intersection of form and function. Adv Exp Med Biol 2012, 748:13-40.
20. Figge M.T., Reichert A.S., Meyer-Hermann M., Osiewacz H.D. Deceleration of fusion-fission cycles improves mitochondrial quality control during aging. PLoS Comput Biol 2012, 8:e1002576.
21. Fijolek J., Wiatr E., Rowinska-Zakrzewska E., Giedronowicz D., Langfort R., Chabowski M., et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers 2006, 21:81-87.
22. Frank S., Gaume B., Bergmann-Leitner E.S., Leitner W.W., Robert E.G., Catez F., et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 2001, 1:515-525.
23. Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 2006, 1:285-295.
24. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
25. Gifford G., Paul J., Vasey P.A., Kaye S.B., Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004, 10:4420-4426.
26. Hirama M., Isonishi S., Yasuda M., Ishikawa H. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol Rep 2006, 16:997-1002.
27. Hu J., Friedman E. Depleting mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer 2010, 1:803-811.
28. Hüttemann M., Pecina P., Rainbolt M., Sanderson T.H., Kagan V.E., Samavati L., et al. The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: from respiration to apoptosis. Mitochondrion 2011, 11:369-381.
29. Ishida S., McCormick F., Smith-McCune K., Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
30. Isonishi S., Saitou M., Yasuda M., Tanaka T. Mitochondria in platinum resistant cells. Hum Cell 2001, 14:203-210.
31. Janson V., Johansson A., Grankvist K. Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance. Cell Death Dis 2011, 1:e78.
32. Kamal N.S., Soria J.C., Mendiboure J., Planchard D., Olaussen K.A., Rousseau V., et al. International adjuvant lung trial-bio investigators. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010, 16:1206-1215.
33. Koberle B., Tomicic M.T., Usanova S., Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010, 1806:172-182.
34. Leboucher G.P., Tsai Y.C., Yang M., Shaw K.C., Zhou M., Veenstra T.D., et al. Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis. Mol Cell 2012, [Epub ahead of print].
35. Liang X.J., Finkel T., Shen D.W., Yin J.J., Aszalos A., Gottesman M.M. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 2008, 6:1499-1506.
36. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010, 20:S609-S631.
37. McDonald E.S., Randon K.R., Knight A., Windebank A.J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005, 18:305-313.
38. McWhinney S.R., Goldberg R.M., McLeold H.L. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009, 1:10-16.
39. Michaud W.A., Nichols A.C., Mroz E.A., Faquin W.C., Clark J.R., Begum S., et al. Bcl 2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 2009, 15:1645-1654.
40. Nur-E-Kamal A., Gross S.R., Pan Z., Balklava Z., Ma J., Liu L.F. Nuclear trans location of cytochrome c during apoptosis. J Biol Chem 2004, 279:24911-24914.
41. Okamoto K., Shaw J.M. Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. Annu Rev Genet 2005, 39:503-536.
42. Olaussen K.A. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin. Cancer Biol Ther 2009, 8:1922-1923.
43. Osman C., Voelker D.R., Langer T. Making heads or tails of phospholipids in mitochondria. J Cell Biol 2011, 192:7-16.
44. Pasetto L.M., D'Andrea M.R., Brandes A.A., Rossi E., Monfardini S. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 2006, 60:59-75.
45. Pinho M.B., Costas F., Sellos J., Dienstmann R., Andrade P.B., Herchenhorn D., et al. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urol Oncol 2009, 27:382-390.
46. Pisu M.B., Roda E., Guioli S., Avella D., Bottone M.G., Bernocchi G. Proliferation and migration of granule cells in the developing rat cerebellum: cisplatin effects. Anat Rec A Discov Mol Cell Evol Biol 2005, 287:1226-1235.
47. Portier B.P., Taglialatela G. Bcl 2 localized at the nuclear compartment induces apoptosis after transient overexpression. Biol Chem 2006, 281:40493-40502.
48. Reddy P.H., Reddy T.P., Manczak M., Calkins M.J., Shirendeb U., Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev 2011, 67:103-118.
49. Reers M., Smiley S.T., Mottola-Hartshorn C., Chen A., Lin M., Chen L.B. Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol 1995, 260:406-417.
50. Ren A., Yan G., You B., Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 2008, 68:2266-2274.
51. Roos W.P., Tsaalbi-Shtylik A., Tsaryk R., Guvercin F., de Wind N., Kaina B. The translation polymerase Rev3L in the tolerance of alkylating anticancer drugs. Mol Pharmacol 2009, 76:927-934.
52. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
53. Santin G., Piccolini V.M., Veneroni P., Barni S., Bernocchi G., Bottone M.G. Different patterns of apoptosis in response to cisplatin in B50 neuroblastoma rat cells. Histol Histopathol 2011, 26:831-842.
54. Schiffer J., Walach N., Lushkov G., Nyska A., Gur R., Pollak L. Effect of the combination of cisplatinum and radiation in the rabbit's brain. Neurol Res 1996, 18:454-456.
55. Shachar S., Ziv O., Avkin S., Adar S., Wittschieben J., Reissner T., et al. Two-polymerase mechanisms dictate error-free and error prone translation DNA synthesis in mammals. EMBO J 2009, 28:383-393.
56. Shen D.W., Ma J., Okabe M., Zhang G., Xia D., Gottesman M.M. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol 2010, 225:822-828.
57. Shirane M., Nakayama K.I. Inherent calcineurin inhibitor FKBP38 targets Bcl 2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003, 5:28-37.
58. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7269.
59. Soldani C., Lazze M.C., Bottone M.G., Tognon G., Biggiogera M., Pellicciari C.E., et al. Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where?. Exp Cell Res 2001, 269:193-201.
60. Soldani C., Scovassi A.I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002, 7:321-328.
61. Tajeddine N., Galluzzi L., Kepp O., Hangen E., Morselli E., Senovilla L., et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27:4221-4232.
62. Tang B.L. Sirt1's systemic protective roles and its promise as a target in antiaging medicine. Transl Res 2011, 157:276-284.
63. Wang G., Reed E., Li Q.Q. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004, 12:955-965.
64. Wang X., Su B., Zheng L., Perry G., Smith M.A., Zhu X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 2009, 19:153-159.
65. Wang Y., Nangia-Makker P., Balan V., Hogan V., Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 2010, 1:e101.
66. Westermann B. Merging mitochondria matters: cellular role and molecular machinery of mitochondrial fusion. EMBO Rep 2002, 3:527-531.
67. Yamasaki M., Makino T., Masuzawa T., Kurokawa Y., Miyata H., Takiguchi S., et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 2011, 104:707-713.
68. Yuan M., Luong P., Hudson C., Gudmundsdottir K., Basu S. c-Abl phosphorylation of DeltaNp63alpha is critical for cell viability. Cell Death Dis 2010, 1:e16.
69. Zorzano A., Liesa M., Sebastián D., Segalés J., Palacín M. Mitochondrial fusion proteins: dual regulators of morphology and metabolism. Semin Cell Dev Biol 2010, 21:566-574.
70. Zou H., Li Y., Liu X., Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999, 274:11549-11556.